|
|
Heartbeam shares are trading lower after the company announced that the FDA issued a "Not Substantially Equivalent" letter regarding its 510(k) submission for its 12-Lead ECG Synthesis Software.
|
|
|
|
12 Health Care Stocks Moving In Friday's Intraday Session
|
|
|
|
Heartbeam Receives NSE Letter From FDA For 12-Lead ECG Synthesis Software; Evaluating Launch Of FDA-Cleared 3d ECG System; To Work With FDA To Resolve NSE Issue
|
|
|
|
HeartBeam Q3 EPS $(0.15) Misses $(0.12) Estimate
|
|
|
|
Earnings Scheduled For November 13, 2025
|
|
|
|
HeartBeam Earnings Preview
|
|